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Abstract: Sepsis is a life-threatening condition and a significant challenge for those working in
intensive care, where it remains one of the leading causes of mortality. According to the sepsis-3
definition, sepsis is characterized by dysregulation of the host response to infection. The TREM-1 gene
codes for the triggering receptor expressed on myeloid cells 1, which is part of the pro-inflammatory
response of the immune system. This study aimed to determine whether the functional TREM-1
rs2234237 single nucleotide polymorphism was associated with mortality in a cohort of 649 Caucasian
patients with sepsis. The 90-day mortality rate was the primary outcome, and disease severity and
microbiological findings were analyzed as secondary endpoints. TREM-1 rs2234237 TT homozygous
patients were compared to A-allele carriers for this purpose. Kaplan–Meier survival analysis revealed
no association between the clinically relevant TREM-1 rs2234237 single nucleotide polymorphism and
the 90-day or 28-day survival rate in this group of septic patients. In addition, the performed analyses
of disease severity and the microbiological findings did not show significant differences between the
TREM-1 rs2234237 genotypes. The TREM-1 rs2234237 genotype was not significantly associated with
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sepsis mortality and sepsis disease severity. Therefore, it was not a valuable prognostic marker for
the survival of septic patients in the studied cohort.
Keywords: 90-day mortality; sepsis; single nucleotide polymorphism; survival analysis; TREM-1
1. Introduction
Sepsis is a life-threatening condition characterized by the severe dysregulation of the host
response to infection [1]. It remains one of the leading causes of death among intensive care unit
(ICU) patients [2]. There is no single standardized test or biomarker for diagnosing sepsis, which is
particularly challenging when no causative infective organism is cultured [3]. The course of sepsis
can be defined as a two-phase process: an infection leads to an overwhelming pro-inflammatory
host response, which in turn leads to uncoordinated upregulation and downregulation of various
inflammatory pathways (impacting on a wide range of cellular and intravascular processes)
resulting in a dysregulated, weakened inflammatory response [4]. Patients often die in this
secondary ‘anti-inflammatory’ phase [5]. This inadequate host response and the largely unexplored
pathomechanisms provide potential targets for the future treatment of sepsis [6]. Studies suggest that
the pro-inflammatory effect of the triggering receptor expressed on myeloid cells 1 (TREM-1) plays
a key role in the host response to an infectious inflammation [7–11]. TREM-1 is expressed on neutrophils
and macrophages associated with the signal transduction molecule DAP12 [7]. Due to the activation of
the DAP12 signaling pathway, TREM-1 amplifies inflammatory response [12]. TREM-1 expression is
enhanced by inflammatory stimuli such as lipopolysaccharides (LPS), a ligand for TLR4, or lipoteichoic
acids [13,14]. It regulates the secretion of interleukin (IL)-8, tumor necrosis factor (TNF)-α and
monocyte chemotactic protein-1 as well as granulocyte differentiation and degranulation [13,14].
Mice models suggest that blocking the TREM-1 signaling pathway positively affects the survival
of mice with bacterial peritonitis and leads to lower levels of pro-inflammatory mediators [15].
Through the activation of blood neutrophils and monocytes, TREM-1 has an important effect on
the acute host response and may therefore be a target for future novel therapies by regulating the
neutrophil inflammatory responses [14,16].
As sepsis is a multifaceted syndrome complex of abnormal pathological, physiological and
biochemical reactions induced by infection [1], the pathophysiology of the disease is diversely
investigated, including analyses of a variety of polymorphisms, proteins and microRNA expression
levels [17]. The genetic component of sepsis pathophysiology is polygenetic, as several single nucleotide
polymorphisms (SNPs) have previously been associated with sepsis outcome and course of disease,
which was also demonstrated in the prospectively enrolled population of this investigation [18–21].
The discovery of genetic variants that affect the expression and protein function of TREM-1
could be of diagnostic and therapeutic relevance. The present genetic association study examined the
functional TREM-1 rs2234237 SNP that induces a change in the amino acid sequence and influences
the biological function of TREM-1 [22]. The rs2234237 SNP has been shown to correlate with sepsis
prognosis in Chinese Han septic patients [23] and to impact atherosclerosis and coronary artery disease
risk as shown in a large Russian population [24]. Furthermore, a clinically relevant association of the
rs2234237 T-allele with the development of pneumonia in mechanically ventilated burn patients was
reported [25]. Thus, this polymorphism is supposed to have biological significance in terms of TREM-1
functionality and to impact on immunological pathways. Further to this, the present study aimed to
assess whether the rs2234237 SNP is associated with sepsis prognosis and 90-day mortality in a large
Caucasian cohort of patients with sepsis. Based on the reported findings of the TREM-1 rs2234237
T-allele as a risk factor for sepsis prognosis in a Chinese Han population and a higher susceptibility to
pneumonia in mechanically ventilated burn patients, we hypothesized that carriage of the TT-genotype
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also predisposes for unfavorable sepsis mortality and disease severity in our prospectively enrolled
cohort of Caucasian patients with sepsis.
2. Materials and Methods
2.1. Study Population
The prospectively enrolled patients in the present study were recruited from three surgical ICUs
at the University Medical Center Goettingen. All patients were part of the GENOSEP database of the
Department of Anesthesiology, comprising a large cohort of septic patients, their baseline characteristics
(medical condition, premedication etc.) as well as relevant clinical parameters. The recruitment began
in 2012, according to the valid sepsis definition at the time [1,26]. To ensure there was a homogeneous
sample, only adult Caucasian patients were enrolled into the study. The following exclusion criteria
were applied: pregnancy, immunosuppressing therapy or chemotherapy, history of heart attack within
6 weeks pre-enrollment, heart failure (New York Heart Association, NYHA IV), infection with human
immunodeficiency virus (HIV), a pre-existing disease that would likely limit patient survival to less
than 28 days, chronic vegetative state, patients already participating in an interventional study and
patients who were study site employees or immediate family members of a study site employee [20].
No patients enrolled in this study were lost to follow-up.
This observational study was approved under the ethical project identification code 15/1/12 by
the Institutional Ethics Committee of the University of Goettingen in Goettingen, Germany, and was
performed in accordance with the provisions of the Declaration of Helsinki. The study was performed
in accordance with relevant guidelines and regulations. The methods were performed in accordance
with the approved guidelines. Written informed consent was obtained either from the patient or their
legal representative.
2.2. Collection of Data
For patients that fulfilled the inclusion criteria, a blood sample was collected within 72 hours
after sepsis onset. The baseline characteristics were collected, including pre-existing illnesses,
surgical history, medications as well as the Acute Physiology and Chronic Health Evaluation (APACHE
II) [27] and Sequential Organ Failure Assessment (SOFA) scores [28] of the day of sepsis onset.
The analyzed clinical data were generated from the electronic patient record system (IntelliSpace
Critical Care and Anesthesia (ICCA), Philips Healthcare, Andover, MA, USA). Daily SOFA scores were
obtained for the length of stay (up to a maximum of 28 days after sepsis onset) to monitor organ failure.
The need for organ support was recorded as a secondary outcome parameter. In order to gather the
primary outcome parameters, a survival verification was obtained after 90 days [29].
All experimental protocols were performed in the laboratories of the Department of Clinical
Pharmacology of the University Medical Center Goettingen. DNA extraction was performed in
two different ways because a part of the blood samples was taken in ethylene diamine tetraacetic
acid (EDTA) blood and another part was taken as peripheral blood mononuclear cells (PBMCs).
For the EDTA blood extraction either a QIAamp® DNA Blood Kit (Qiagen, Hilden, Germany) in a
QIAcube® or an EZ1® DNA Blood Kit (Qiagen, Hilden, Germany) in a BioRobot EZ1® was used.
For the PBMC samples the extraction was performed with an AllPrep DNA Mini Kit (Qiagen, Hilden,
Germany). Genotyping was performed via TaqMan polymerase chain reaction (PCR) with TaqMan®
SNP Genotyping Assay C__15948162_10 and a 7900HT Fast Real-Time PCR System (Life Technologies,
Darmstadt, Germany). The quality and quantity of the DNA extraction was spectrophotometrically
tested. The quality of the genotyping was verified by testing 15% of the samples in duplicate [30].
2.3. Data Analysis
The statistical analyses were performed with the STATISTICA 13 software (version 13.0, StatSoft,
Tulsa, Oklahoma, USA). A p-value <0.05 was considered statistically significant. A log-rank-test was
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used for the Kaplan–Meier survival analysis. A multivariate Cox regression analysis was performed
to exclude the effects of confounders on the survival. The Mann–Whitney-U-Test was performed for
continuous variables while categorical variables were tested with a Pearson chi-square-test [30].
2.4. Availability of Data and Materials
The datasets used and analyzed during the current study are available from the corresponding
author upon reasonable request.
3. Results
3.1. Baseline Characteristics at the Time of Enrolment
This study enrolled 649 septic patients from intensive care. The average age was 63 years with a
standard deviation of 15 and ranged from 18 to 91. A total of 66% of the study population was male.
The mean BMI was 28 with a standard deviation of 6. Furthermore, the sequential organ failure assessment
(SOFA) and acute physiology and chronic health evaluation (APACHE II) scores were evaluated on day 1.
The mean SOFA score was 9.4 ± 3.9 and the APACHE II score was 22 ± 7. The need for organ support at
sepsis onset was 86% for mechanical ventilation, 67% for the use of a vasopressor and 9% for the need for
dialysis. Mechanical ventilation during the observed period was needed by 93%, vasopressor use by 79%
and dialysis by 21% of the patients. The mean length of stay was 20 ± 16 days.
The genotype distribution of TREM-1 rs2234237 was TT: n = 545, AT: n = 98 and AA: n = 6. This led
to an observed minor allele frequency (MAF) of 0.096, almost equal to the expected MAF of 0.102
from the gnomAD—Exomes for a European population [31] reference population. The observed allele
frequencies were consistent with the Hardy–Weinberg equilibrium (p-value: 0.4890).
We pooled the AT and AA genotypes in order to compare the TT homozygotes to the A-allele carries.
At baseline, the TT homozygous patients (n = 545) showed a significantly higher history of myocardial
infarction (6% vs. 1%, p = 0.0290) compared to A-allele carriers (n = 104). Furthermore, at baseline, the
TT homozygous patients’ recent surgical history (27% elective surgery, 54% emergency surgery, 19% no
surgery) differed significantly from the A-allele carriers’ (40% elective surgery, 49% emergency surgery,
11% no surgery, p = 0.0103). All baseline characteristics data can be obtained from Table 1.
Table 1. Patient baseline characteristics with regard to TREM-1 rs2234237 genotypes.
All (n = 649) AA/AT (n = 104) TT (n = 545) p-Value
General
Age in years 63 ± 15 64 ± 14 63 ± 15 0.5392
Sex: Male (%) 66 66 66 0.9254
BMI 28 ± 6 27 ± 6 28 ± 6 0.9725
Severity
SOFA Day 1 9.4 ± 3.9 9.0 ± 4.1 9.4 ± 3.8 0.1421
APACHE II Day 1 22 ± 7 21 ± 7 22 ± 7 0.3042
Septic shock (%) 51 57 50 0.1800
Days in septic shock 2 ± 3 2 ± 3 2 ± 3 0.1453
Procalcitonin ng/dl Day 1 10 ± 29 10 ± 26 10 ± 30 0.8157
Comorbidities (%)
Hypertension 54 50 55 0.3804
History of myocardial infarction 5 1 6 0.0290
Chronic obstructive pulmonary disease 15 14 15 0.8703
Bronchial asthma 3 2 3 0.6275
Renal dysfunction 10 11 10 0.9262
Noninsulin-dependent diabetes mellitus 9 11 8 0.4805
Insulin-dependent diabetes mellitus 10 11 10 0.9712
Chronic liver disease 6 5 7 0.4898
History of cancer 15 20 15 0.2387
History of stroke 6 4 6 0.3410
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Table 1. Cont.
All (n = 649) AA/AT (n = 104) TT (n = 545) p-Value
Dementia 3 4 3 0.7800
Rheumatoid arthritis 1 0 1 0.2824
Recent surgical history (%) 0.0103
Elective surgery 29 40 27
Emergency surgery 53 49 54
No surgery 18 11 19
Organ support during observation period (%)
Mechanical ventilation 93 92 94 0.6332
Use of vasopressor 79 78 79 0.7186
Renal replacement therapy 21 18 21 0.5133
Organ support on sepsis onset (%)
Mechanical ventilation 86 87 86 0.8200
Use of vasopressor 67 64 67 0.5878
Renal replacement therapy 9 8 9 0.6681
Length of stay:
LOS ICU 20 ± 16 21 ± 17 20 ± 16 0.7486
Footnote: SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation;
LOS, Length of stay; ICU, Intensive care unit; BMI, body mass index.
As a measure of organ dysfunction, the necessity of organ support (mechanical ventilation, use of
vasopressors and renal replacement therapy) on sepsis onset and during observation period was
studied, but did not reveal significant differences.
3.2. Mortality Analysis
The primary outcome parameter was 90-day mortality. In the performed Kaplan–Meier
survival analysis, A-allele carriers showed a lower mortality rate than the TT homozygous carriers
(27.88% vs. 30.64%, respectively); however, the result was not significant (p = 0.5203) (Figure 1).
The 28-day survival analysis showed that A-allele carriage was associated with a lower mortality rate
than TT homozygotes (16.35% vs. 20.55%), but this difference did not achieve statistical significance
(p = 0.3257) (Figure 2).
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Figure 1. Kaplan–Meier 90-day survival analysis with regard to TREM-1 rs2234237 genotypes.
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3.3. Multivariate Analysis
In order to recognize the effects of the potential confounders and variables of the baseline
characteristics on the 90-day mortality, we performed a multivariate Cox regression analysis.
Age, body mass index (BMI), SOFA score at day 1, APACHE II score at day 1 and male gender were
included as baseline variables. The presence of myocardial infarction as pre-existing medical condition
was included as a potential confounder due to the results of the patient baseline characteristics.
Our results show that age, SOFA score day 1 and APACHE II score day 1 had a significant impact on
survival. In contrast, the TREM-1 rs2234237 TT-genotype did not significantly impact upon survival
(hazard ratio: 1.11, 95% CI: 0.74–1.65, p-value = 0. 6098 (Table 2)).
Table 2. Cox regression analysis (90 days) with regard to TREM-1 rs2234237 genotypes.
Variable Hazard Ratio 95% CI p-Value
Age 1.0270 1.0150–1.0391 0.0000
Body mass index 0.9795 0.9544–1.0053 0.1181
SOFA score 1.0704 1.0228–1.1203 0.0034
APACHE II score 1.0335 1.0046–1.0633 0.0226
Male gender 1.0481 0.7771–1.4137 0.7582
Myocardial infarction 1.2061 0.6956–2.0913 0.5046
TREM-1 rs2234237 TT genotype 1.1093 0.7448–1.6522 0.6098
Footnote: SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation.
3.4. Disease Severity
In order to evaluate the association between the TREM-1 rs2234237 genotypes and disease
severity, the authors examined the SOFA scores, organ-specific SOFA sub-scores, organ support and
various hematological and biochemical parameters. Organ support was divided in three subgroups:
ventilation-free days, vasopressor-free days and dialysis-free days. The analyzed blood tests were
leucocytes, C-reactive protein (CRP), and procalcitonin, as well as parameters for liver function,
kidney function and coagulation. The observation period was 28 days after sepsis onset, unless the
patient was discharged prior to this or deceased.
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We found no significant differences in disease severity between TREM-1 rs2234237 genotypes
(Table 3).
Table 3. Disease severity with regard to TREM-1 rs2234237 genotypes.
All (n = 649) AA/AT (n = 104) TT (n = 545) p-Value
General
SOFA 7 ± 4 7 ± 4 7 ± 3 0.4717
SOFA respiratory score 2 ± 1 2 ± 1 2 ± 1 0.8800
SOFA cardiovascular score 2 ± 1 2 ± 1 2 ± 1 0.7582
SOFA central nervous system score 2 ± 1 2 ± 1 2 ± 1 0.1310
SOFA renal score 1 ± 1 1 ± 1 1 ± 1 0.8692
SOFA coagulation score 0 ± 1 0 ± 1 0 ± 1 0.2439
SOFA hepatic score 0 ± 1 0 ± 1 0 ± 1 0.8126
Organ support free days
Ventilation free days 5 ± 5 4 ± 5 5 ± 5 0.8157
Vasopressor free days 10 ± 7 10 ± 7 10 ± 7 0.5074
Dialysis free days 14 ± 8 14 ± 8 14 ± 8 0.7018
Ventilation free days/observation days (%) 66 ± 32 65 ± 34 67 ± 31 0.9150
Vasopressor free days/observation days (%) 34 ± 30 34 ± 30 33 ± 30 0.7081
Dialysis free days/observation days (%) 9 ± 22 9 ± 22 10 ± 23 0.6751
Inflammatory values:
Leucocytes (1000/µL) 13 ± 5 13 ± 5 13 ± 5 0.4353
CRP (mg/L) 151 ± 87 164 ± 89 148 ± 86 0.1946
Procalcitonin (ng/dL) 4 ± 9 5 ± 13 4 ± 8 0.9562
Kidney values
Urine output (ml/day) 2980 ± 1333 2864 ± 1280 3002 ± 1343 0.2934
Urine output (ml/kg/h) 2 ± 1 2 ± 1 2 ± 1 0.7470
Creatinine (mg/dL) 1.2 ± 1 1.2 ± 0.8 1.2 ± 1 0.7346
Liver values
AST (GOT) (IU/L) 168 ± 595 114 ± 229 177 ± 642 0.3071
ALT (GPT) (IU/L) 93 ± 188 74 ± 142 97 ± 195 0.0630
Bilirubin (mg/dL) 1.2 ± 2 1.1 ± 1.7 1.2 ±2 0.9725
Central nervous system
GCS 10 ± 3 10 ± 3 10 ± 3 0.1553
Coagulation:
Thrombocytes (1000/µL) 296 ± 152 274 ± 131 300 ± 155 0.1810
Footnote: SOFA, sequential organ failure assessment; CRP, C-reactive protein; GCS, Glasgow Coma Scale; AST,
aspartate amino transferase; GOT, glutamic oxalo acetic transaminase; ALT, alanine aminotransferase; GPT,
glutamic-pyruvic transaminase.
Furthermore, the observed microbiological findings were compared, but also revealed no
significant differences.
4. Discussion
The TREM-1 receptor on neutrophils and macrophages has been shown to have a pro-inflammatory
effect on the host response to infection. Previous studies have demonstrated that the blocking of TREM-1
signaling is associated with a reduction of inflammatory mediators such as IL-1, TNF-α, Monocyte
chemoattractant protein 1 (MCP-1) and interferon (IFN)-γ and prolonged survival in mice with bacterial
infection [15]. Considering the need for novel diagnostic approaches in the treatment of sepsis [4,32],
other studies discussed the role of soluble TREM-1 as a potential biomarker in sepsis [33]. The aim of
our study was to investigate the impact of a genetic variant of the TREM-1 gene, which is located on
chromosome 6, on the survival of patients with sepsis. We examined the functional TREM-1 rs2234237
SNP, a variation in exon 2 of the TREM-1 gene.
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An accordance with the a priori hypothesis, this study found that TREM-1 rs2234237
TT-genotype carriers had an unfavorable 90- and 28-day survival rate compared to A-allele
carriers (30.64% vs. 27.88%). However these results were not statistically significant (p = 0.5203).
Furthermore, the performed multivariate Cox regression analysis did not significantly show that the
TREM-1 rs2234237 TT-genotype is a valuable prognostic marker for the survival of septic patients.
According to the Cox regression analysis, the effect of the TREM-1 rs2234237 TT genotype on 90-day
survival could be in the range of −25.5% to +65.2% (hazard ratio 95% CI: 0.7448–1.6522), which was
however not significantly detected in our cohort (p = 0.6098). Our findings are consistent with previous
studies in Chinese Han populations, which also did not reveal a significant impact of the TREM-1
rs2234237 genotype on the 28-day outcome of patients in septic shock [22] or the development of
severe sepsis [34]. However, different population allele frequencies and a divergent study design
needed to be considered in these studies.
As secondary endpoints, the patient baseline characteristic and disease severity were examined
with regard to the TREM-1 rs2234237 genotypes. These analyses showed that A-allele carries
had a significantly lower history of myocardial infarction compared to TT homozygous patients.
Moreover, A-allele carriers differed in their recent surgical history, and had significantly more elective
surgeries and less emergency surgeries as well as less conservative treatments as the reason for recent
consultations. These findings suggest that TREM-1 may play a role in a range of disease processes,
and this is certainly an area that requires further exploration and investigation. We supposed that the
functional TREM-1 rs2234237 SNP that induces a change in the amino acid sequence and influences the
biological function of TREM-1 [22] might affect sepsis mortality and disease severity in a relatively large
cohort of prospectively enrolled septic Caucasian patients. However, our a priori hypothesis could not
be verified by the performed investigations and thus needs to be rejected or possibly studied in other
cohorts or with different study designs. The results do not allow us to draw conclusions regarding
the contribution of the TREM-1 molecule to the pathophysiology of the disease. Possible alterations
of TREM-1 functionality may not be relevant to the etiology and pathophysiology of the disease in
the studied cohort. To further investigate alterations in functionality, TREM-1 protein expressions
(i.e., soluble TREM-1), RNA expressions or TREM-1 protein function should be studied as direct
measures of pathophysiology in sepsis.
As this study is a genetic association study, multiplicity, population stratification and inadequate
sample size need to be acknowledged as potential limitations. While a well-defined prospectively
enrolled homogeneous cohort of patients is certainly a strength of our investigation, the monocentric
design and focus on Caucasian ethnicity need to be considered as limitations. The study was conducted
in a single center and findings therefore need to be further validated in independent cohorts from
other centers to assess their generalizability, also including different ethnicities. Moreover, the additive
effects of other SNPs in the TREM-1 gene—such as rs2234246, rs7768162 or rs9471535—on sepsis
outcome have not been investigated in this study, but need to be considered. Furthermore, a power
calculation to determine a sample size with adequate power at the beginning of the investigation could
not be conducted, because the effect of the TREM-1 rs2234237 polymorphism on 90-day mortality
in patients with sepsis was unknown. Though, we assumed that the relatively rare genetic variant
rs2234237 (MAF of 0.102; according to gnomAD—Exomes for a European population) needs to show
an effect of at least 15% mortality reduction in our cohort of 649 septic Caucasians in order to act as a
prognostic marker for survival in patients with sepsis. Such an effect of 15% mortality reduction would
have shown a power of 0.911. Accordingly, the observed slight effect of 2.76% mortality reduction
(27.88% vs. 30.64% for A-allele carriers and TT homozygous carriers, respectively) in a representative
cohort of 649 septic Caucasians means that the polymorphism rs2234237 cannot act as a useful predictor
of survival in routine clinical practice. In addition, our analysis of disease severity was performed in a
univariate model and not adjusted in a multivariate analysis.
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5. Conclusions
To the best of the authors’ knowledge, this is the first study investigating the effects of the
TREM-1 rs2234237 genotype on the mortality and disease severity of Caucasian patients with sepsis.
In conclusion, the TREM-1 rs2234237 genotype is not significantly associated with sepsis mortality or
disease severity.
Author Contributions: Conceptualization, J.R., C.M., J.H., A.-F.P., M.G., M.Q., I.B. and A.M.; Data curation,
J.R., C.M., B.B., K.K., T.B., J.S. and B.S.; Formal analysis, J.R., C.M., T.B. and M.T.; Funding acquisition, A.M.;
Investigation, J.R., C.M., B.B., K.K., B.S. and I.B.; Methodology, J.H., A.-F.P., M.T., I.B. and A.M.; Project
administration, B.B., J.H., A.-F.P., M.G., K.K., J.S., M.T. and M.Q.; Resources, M.G., M.T., M.Q. and A.M.;
Software, J.H.; Supervision, J.H., T.B., M.Q. and A.M.; Validation, T.B., B.S. and A.M.; Visualization, J.R. and C.M.;
Writing—original draft, J.R., C.M. and J.H.; Writing—review and editing, B.B., J.H., A.-F.P., M.G., K.K., T.B., J.S.,
M.T., B.S., M.Q., I.B. and A.M.
Funding: This research was funded by the VolkswagenStiftung, grant number ZN3168.
Acknowledgments: The authors thank the staff of the ICUs of the Department of Anesthesiology and Department
of General and Visceral Surgery Goettingen, all of whom were involved in patient care and monitoring.
Conflicts of Interest: The authors declare no conflict of interest. The funder had no role in the design of the study;
in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish
the results.
References
1. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.;
Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for
Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [CrossRef] [PubMed]
2. Angus, D.C. The lingering consequences of sepsis: A hidden public health disaster? JAMA 2010, 304, 1833–1834.
[CrossRef] [PubMed]
3. Vincent, J.-L. The clinical challenge of sepsis identification and monitoring. PLoS Med. 2016, 13, e1002022.
[CrossRef] [PubMed]
4. Boomer, J.S.; Green, J.M.; Hotchkiss, R.S. The changing immune system in sepsis. Virulence 2014, 5, 45–56.
[CrossRef] [PubMed]
5. Boomer, J.S.; Shuherk-Shaffer, J.; Hotchkiss, R.S.; Green, J.M. A prospective analysis of lymphocyte phenotype
and function over the course of acute sepsis. Crit. Care 2012, 16. [CrossRef] [PubMed]
6. Delano, M.J.; Ward, P.A. The immune system’s role in sepsis Progression, resolution and long-term outcome.
Immunol. Rev. 2016, 274, 330–353. [CrossRef] [PubMed]
7. Bouchon, A.; Facchetti, F.; Weigand, M.A.; Colonna, M. TREM-1 amplifies inflammation and is a crucial
mediator of septic shock. Nature 2001, 410, 1103–1107. [CrossRef] [PubMed]
8. Haselmayer, P.; Daniel, M.; Tertilt, C.; Salih, H.R.; Stassen, M.; Schild, H.; Radsak, M.P. Signaling pathways
of the TREM-1- and TLR4-mediated neutrophil oxidative burst. J. Innate Immun. 2009, 1, 582–591. [CrossRef]
[PubMed]
9. Bleharski, J.R.; Kiessler, V.; Buonsanti, C.; Sieling, P.A.; Stenger, S.; Colonna, M.; Modlin, R.L. A role for
triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive
phases of the immune response. J. Immunol. 2003, 170, 3812–3818. [CrossRef] [PubMed]
10. Gibot, S.; Alauzet, C.; Massin, F.; Sennoune, N.; Faure, G.C.; Béné, M.; Lozniewski, A.; Bollaert, P.; Lévy, B.
Modulation of the triggering receptor expressed on myeloid cells–1 pathway during pneumonia in rats.
J. Infect. Dis. 2006, 194, 975–983. [CrossRef] [PubMed]
11. Colonna, M.; Facchetti, F. TREM-1 (Triggering Receptor Expressed on Myeloid Cells): A new player in acute
inflammatory responses. J. Infect. Dis. 2003, 187, 397–401. [CrossRef] [PubMed]
12. Lanier, L.L.; Corliss, B.C.; Wu, J.; Leong, C.; Phillips, J.H. Immunoreceptor DAP12 bearing a tyrosine-based
activation motif is involved in activating NK cells. Nature 1998, 391, 703–707. [CrossRef] [PubMed]
13. Suh, H.C.; Benoukraf, T.; Shyamsunder, P.; Yin, T.; Cao, Q.; Said, J.; Lee, S.; Lim, R.; Yang, H.; Salotti, J.; et al.
LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBPε in granulocytes. Sci. Rep.
2017, 7, 46440. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 301 10 of 11
14. Bouchon, A.; Dietrich, J.; Colonna, M. Cutting edge: Inflammatory responses can be triggered by TREM-1,
a novel receptor expressed on neutrophils and monocytes. J. Immunol. 2000, 164, 4991–4995. [CrossRef]
[PubMed]
15. Wang, F.; Liu, S.; Wu, S.; Zhu, Q.; Ou, G.; Liu, C.; Wang, Y.; Liao, Y.; Sun, Z. Blocking TREM-1 signaling
prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell. Immunol. 2012, 272, 251–258.
[CrossRef] [PubMed]
16. Zeng, H.; Ornatowska, M.; Joo, M.S.; Sadikot, R.T. TREM-1 expression in macrophages is regulated at
transcriptional level by NF-κB and PU.1. Eur. J. Immunol. 2007, 37, 2300–2308. [CrossRef] [PubMed]
17. Rogobete, A.F.; Sandesc, D.; Bedreag, O.H.; Papurica, M.; Popovici, S.E.; Bratu, T.; Popoiu, C.M.; Nitu, R.;
Dragomir, T.; AAbed, H.I.M.; et al. MicroRNA expression is associated with sepsis disorders in critically ill
polytrauma patients. Cells 2018, 7, 271. [CrossRef] [PubMed]
18. Mewes, C.; Büttner, B.; Hinz, J.; Alpert, A.; Popov, A.-F.; Ghadimi, M.; Beissbarth, T.; Tzvetkov, M.; Jensen, O.;
Runzheimer, J.; et al. CTLA-4 genetic variants predict survival in patients with sepsis. J. Clin. Med. 2019, 8, 70.
[CrossRef] [PubMed]
19. Mewes, C.; Büttner, B.; Hinz, J.; Alpert, A.; Popov, A.F.; Ghadimi, M.; Beissbarth, T.; Tzvetkov, M.; Shen-Orr, S.;
Bergmann, I.; et al. The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in
Caucasian patients with sepsis. Sci. Rep. 2018, 8, 15140. [CrossRef] [PubMed]
20. Mansur, A.; Hinz, J.; Hillebrecht, B.; Bergmann, I.; Popov, A.F.; Ghadimi, M.; Bauer, M.; Beissbarth, T.;
Mihm, S. Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic
polymorphism rs11568821. J. Investig. Med. 2014, 62, 638–643. [CrossRef] [PubMed]
21. Mansur, A.; Liese, B.; Steinau, M.; Ghadimi, M.; Bergmann, I.; Tzvetkov, M.; Popov, A.F.; Beissbarth, T.;
Bauer, M.; Hinz, J. The CD14 rs2569190 TT genotype is associated with an improved 30-day survival in
patients with sepsis: A prospective observational cohort study. PLoS ONE 2015, 10, e0127761. [CrossRef]
[PubMed]
22. Peng, L.; Li, J.; Zhou, G.; Deng, L.; Yao, H. Relationships between genetic polymorphisms of triggering
receptor expressed on myeloid cells-1 and septic shock in a Chinese Han population. World J. Emerg. Med.
2015, 6, 123–130. [CrossRef] [PubMed]
23. Su, L.; Liu, C.; Li, C.; Jiang, Z.; Xiao, K.; Zhang, X.; Li, M.; Yan, P.; Feng, D.; Xie, L. Dynamic changes in
serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and its gene polymorphisms are
associated with sepsis prognosis. Inflammation 2012, 35, 1833–1843. [CrossRef] [PubMed]
24. Golovkin, A.S.; Ponasenko, A.V.; Khutornaya, M.V.; Kutikhin, A.G.; Salakhov, R.R.; Yuzhalin, A.E.;
Zhidkova, I.I.; Barbarash, O.L.; Barbarash, L.S. Association of TLR and TREM-1 gene polymorphisms
with risk of coronary artery disease in a Russian population. Gene 2014, 550, 101–109. [CrossRef] [PubMed]
25. Rivera-Chávez, F.A.; Huebinger, R.M.; Burris, A.; Liu, M.-M.; Minei, J.P.; Hunt, J.L.; Arnoldo, B.D.; Barber, R.C.
A TREM-1 polymorphism A/T within the exon 2 is associated with pneumonia in burn-injured patients.
ISRN Inflamm. 2013, 2013, 431739. [CrossRef] [PubMed]
26. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.H.; Sibbald, W.J.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
Chest 1992, 101, 1644–1655. [CrossRef] [PubMed]
27. Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A severity of disease classification
system. Crit. Care Med. 1985, 13, 818–829. [CrossRef] [PubMed]
28. Vincent, J.L.; de Mendonça, A.; Cantraine, F.; Moreno, R.; Takala, J.; Suter, P.M.; Sprung, C.L.; Colardyn, F.;
Blecher, S. Use of the Sofa score to assess the incidence of organ dysfunction/failure in intensive care units:
Results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European
Society of Intensive Care Medicine. Crit. Care Med. 1998, 26, 1793–1800. [CrossRef] [PubMed]
29. Khamsi, R. Execution of sepsis trials needs an overhaul, experts say. Nat. Med. 2012, 18, 998–999. [CrossRef]
[PubMed]
30. Hinz, J.; Büttner, B.; Kriesel, F.; Steinau, M.; Frederik Popov, A.; Ghadimi, M.; Beissbarth, T.; Tzvetkov, M.;
Bergmann, I.; Mansur, A. The FER rs4957796 TT genotype is associated with unfavorable 90-day survival in
Caucasian patients with severe ARDS due to pneumonia. Sci. Rep. 2017, 7, 9887. [CrossRef] [PubMed]
31. rs2234237 Reference SNP (rs) Report—dbSNP—NCBI. Available online: https://www.ncbi.nlm.nih.gov/
snp/rs2234237#frequency_tab (accessed on 21 November 2018).
J. Clin. Med. 2019, 8, 301 11 of 11
32. Hotchkiss, R.S.; Monneret, G.; Payen, D. Sepsis-induced immunosuppression: From cellular dysfunctions to
immunotherapy. Nat. Rev. Immunol. 2013, 13, 862–874. [CrossRef] [PubMed]
33. Brenner, T.; Uhle, F.; Fleming, T.; Wieland, M.; Schmoch, T.; Schmitt, F.; Schmidt, K.; Zivkovic, A.R.;
Bruckner, T.; Weigand, M.A.; et al. Soluble TREM-1 as a diagnostic and prognostic biomarker in patients
with septic shock: An observational clinical study. Biomarkers 2017, 22, 63–69. [CrossRef] [PubMed]
34. Chen, Q.; Zhou, H.; Wu, S.; Wang, H.; Lv, C.; Cheng, B.; Xie, G.; Fang, X. Lack of association between TREM-1
gene polymorphisms and severe sepsis in a Chinese Han population. Hum. Immunol. 2008, 69, 220–226.
[CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
